-
DAMPs and NLRP3 Inflammasome Response in Fatty Liver Grafts Preservation in Different Preservation Solutions
-
Daratumumab for Desensitization and Antibody Mediated Rejection Treatment in Highly-HLA Sensitized Patients
-
DCD vs DBD Liver Transplantation: Equivalent Charges and Similar Survival- An Effective Expansion of the Donor Pool
-
dd-cfDNA as a Risk Factor for Initiating De-Novo Donor Specific Antibodies in Heart Transplantation
-
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
-
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
-
De Novo DSA in the Setting of Stable Renal Allograft Function Does Not Impair Long-Term Graft Survival
-
De Novo Malignancy after Liver Transplantation for Alcoholic Cirrhosis: Incidence and Outcomes
-
De Novo NAFLD Post-Liver Transplant is Defined by Altered Lipid Metabolism and Mitochondrial Dysfunction
-
De Novo Use of Envarsus (LCPT) in African American and Elderly Kidney Transplant Recipients: An Early Single Center Experience
- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 223
- Next Page »